ClinicalTrials.gov

History of Changes for Study: NCT04258033
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation
Latest version (submitted February 5, 2020) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 5, 2020 None (earliest Version on record)
Comparison Format:

Scroll up to access the controls

Study NCT04258033
Submitted Date:  February 5, 2020 (v1)

Open or close this module Study Identification
Unique Protocol ID: PLB1001-II-NSCLC-01
Brief Title: A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation
Official Title: A Phase II, Open-label, Multicenter and Multi-cohorts Study to Evaluate the Efficacy and Safety of PLB1001 in Advanced Non-small Cell Lung Cancer With c-Met Dysregulation
Secondary IDs:
Open or close this module Study Status
Record Verification: February 2020
Overall Status: Recruiting
Study Start: January 17, 2020
Primary Completion: December 31, 2022 [Anticipated]
Study Completion: December 31, 2024 [Anticipated]
First Submitted: February 3, 2020
First Submitted that
Met QC Criteria:
February 5, 2020
First Posted: February 6, 2020 [Actual]
Last Update Submitted that
Met QC Criteria:
February 5, 2020
Last Update Posted: February 6, 2020 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Beijing Pearl Biotechnology Limited Liability Company
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.
Detailed Description: PLB1001 will be administrated 200mg twice daily. The treatment will be discontinued for the patients who experience disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent. A cycle of study treatment will be defined as 28 days of continuous dosing. The study includes 4 cohorts.
Open or close this module Conditions
Conditions: Non-small Cell Lung Cancer
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Single Group Assignment
Number of Arms: 1
Masking: None (Open Label)
Allocation: N/A
Enrollment: 185 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: PLB1001
Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
Drug: PLB1001
PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
Other Names:
  • Bozitinib
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Objective response rate
[ Time Frame: 2 years ]

Objective response rate will be determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Objective response rate is defined as the percentage of patients who experienced either a complete response (CR) or partial response (PR) from first administration of trial treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Secondary Outcome Measures:
1. Progression free survival
[ Time Frame: 2 years ]

Progression free survival is defined as the time (in months) from the first administration of trial treatment to the date of the first documentation of PD or death due to any cause. PD is defined as at least a 20 % increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
2. Overall survival
[ Time Frame: 4 years ]

Overall survival is defined as the time (in months) from first trial treatment administration to the date of death.
3. Disease control rate
[ Time Frame: 2 years ]

Disease control rate according to RECIST 1.1 is the percentage of patients who experienced either a complete response (CR), partial response (PR) or stable disease (SD).
4. Time to response
[ Time Frame: 2 years ]

Time to response according to RECIST 1.1 is the time from the first trial treatment administration to the CR/PR (whichever is first) criteria are first met. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
5. Duration of response
[ Time Frame: 2 years ]

Duration of response according to RECIST 1.1 is the time from when the CR/PR (whichever is first) criteria are first met until progression of disease (PD) or death due to any cause. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
6. Occurrence of Treatment emergent adverse event (TEAEs)
[ Time Frame: 2 years ]

This outcome measure will be presented as the percentage of subjects with any (serious) adverse event (AE). Percentages are calculated using total number of subjects per treatment cohort as the denominator.
7. Maximum Plasma concentration (Cmax) of drug
[ Time Frame: Cycle 1, Day 1 and on Cycle 1, Day 15 ]

In the study some Pharmacokinetics (PK) profiles of PLB1001 will be obtained following administration of PLB-1001 at pre-dose and at the 0.5, 2, 4, 6,10 hours time points on Cycle 1, Day 1 and on Cycle 1, Day 15.
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • Signed Informed Consent Form
  • Age≥18 years
  • Histologically or cytologically confirmed advanced non-small cell lung cancer
  • Must have evidence of c-Met dysregulation from the results of molecular pre-screening evaluations
  • At least one measurable lesion as per RECIST v1.1
  • Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1
  • ECOG Performance Status of 0-1.

Exclusion Criteria:

  • Symptomatic central nervous system (CNS) metastases that are neurologically unstable or requiring increasing doses of steroids to control, and patients with any CNS deficits.
  • Clinically significant, uncontrolled heart diseases Unstable angina History of documented congestive heart failure (New York Heart Association functional classification > II) Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg Arrhythmias
  • Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except for alopecia
  • Major surgery within 4 weeks prior to starting PLB1001
  • Previous anti-cancer and investigational agents within 2 weeks before first dose of PLB1001. If previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of PLB1001
  • Pregnant or nursing women
  • Involved in other clinical trials < 2 weeks prior to Day. If previous treatment of clinical trial is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of PLB1001.
Open or close this module Contacts/Locations
Central Contact Person: Weizhe Xue, Ph. D
Telephone: +86-10-84148931
Email: xueweizhe@pearlbio.cn
Study Officials: Yilong Wu, MD
Principal Investigator
Guangdong Provincial People's Hospital
Locations: China, Guangdong
Guangdong General Hospital
[Recruiting]
Guangzhou, Guangdong, China, 510080
Contact:Contact: Jinji Yang, MD +86-20-83827812 Ext. 50810 yangjinji@gdph.org.cn
Contact:Principal Investigator: Yilong Wu, MD
Contact:Sub-Investigator: Jinji Yang, MD
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services